Data-augmented machine learning redefines the effective concentration of eculizumab in complement blood disorders

Abstract excerpt

Eculizumab, a humanized monoclonal antibody targeting the complement lytic pathway protein C5, has demonstrated high efficacy in the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have highlighted patients who exhibit a lack of treatment response, necessitating an increase in th...

Topics

Open a Topic to create a Post that cites this publication.

• Algorithms
• Clinical Decision-Making
• Combined Modality Therapy
• Disease Management
• Disease Susceptibility
• Hemoglobinuria, Paroxysmal
• Prognosis
• Treatment Outcome

Identifiers and source

Literature Corpus work

b5c8d248-2f8a-5e0f-a0d6-83c4cd2cdba1

DOI

10.64898/2025.12.13.25342192